Literature DB >> 8392030

Can determination of the proliferative capacity of the nontumor portion predict the risk of tumor recurrence in the liver remnant after resection of human hepatocellular carcinoma?

J H Chiu1, L H Wu, H L Kao, H M Chang, S H Tsay, C C Loong, G Y Chau, W Y Lui.   

Abstract

To test the hypothesis that increased proliferative capacity of cells in a liver remnant is a risk factor for tumor recurrence in patients who have undergone liver resection for hepatocellular carcinoma, DNA flow-cytometric measurement and cell-cycle analysis of the nontumor parts of resected hepatocellular carcinomas (tumor size < 5 cm) were performed. The disease-free survival rates 1, 2, 3 and 4 yr after surgery were 64%, 58%, 43%, and 36%, respectively. Proliferative capacity (fractions of synthetic, postsynthetic and mitotic phases) of the nontumor parts, irrespective of liver pathology, was higher than that of normal liver and statistically lower than that of tumor parts from resected hepatocellular carcinoma specimens. Livers with chronic active hepatitis (+) and with hepatocyte dysplasia (-) had significantly lower proliferative activity than did those with chronic active hepatitis (-) and with hepatocyte dysplasia (+), respectively [corrected]. We saw no significant difference in proliferative capacity between patients with and without cirrhosis. Disease-free-survival analysis showed that the presence of liver pathology (hepatitis B infection, cirrhosis, chronic active hepatitis and hepatocyte dysplasia) was not the factor linked to tumor recurrence in the liver remnant and that a marked increase in proliferative capacity (> or = 18%), regardless of liver pathology, was the risk factor linked to tumor recurrence after liver resection. We conclude that there is some degree of increased proliferative capacity in the nontumor parts of resected hepatocellular carcinomas and that a marked increase in the proliferative capacity (> or = 18%) of the nontumor part is a significant risk factor in predicting tumor recurrence in the liver remnant after liver resection.

Entities:  

Mesh:

Year:  1993        PMID: 8392030

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  4 in total

1.  Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma.

Authors:  G Y Chau; C W Wu; W Y Lui; T J Chang; H L Kao; L H Wu; K L King; C C Loong; C Y Hsia; C W Chi
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

Review 2.  Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma.

Authors:  R Tung-Ping Poon; S T Fan; J Wong
Journal:  Ann Surg       Date:  2000-07       Impact factor: 12.969

3.  Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma.

Authors:  S Kubo; S Nishiguchi; T Shuto; H Tanaka; T Tsukamoto; K Hirohashi; T Ikebe; K Wakasa; T Kuroki; H Kinoshita
Journal:  Jpn J Cancer Res       Date:  1999-02

4.  Clinical, Epidemiological and Histopathological Aspects in Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation

Authors:  Nathalia Martines Tunissiolli; Márcia Maria Urbanin Castanhole-Nunes; Érika Cristina Pavarino; Renato Ferreira da Silva; Rita de Cássia Martins Alves da Silva; Eny Maria Goloni-Bertollo
Journal:  Asian Pac J Cancer Prev       Date:  2018-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.